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2Abstract
Recovery from coronavirus disease 2019 (COVID-19) will be principally defined in terms of 
remission from respiratory symptoms, however both clinical and animal studies have shown 
that coronaviruses may spread to the nervous system. A systematic search on previous viral 
epidemics revealed that while there has been relatively little research in this area, clinical 
studies have commonly reported neurological disorders and cognitive difficulties. Little is 
known with regard to their incidence, duration or underlying neural basis. The hippocampus 
appears to be particularly vulnerable to coronavirus infections, thus increasing the probability 
of post-infection memory impairment, and acceleration of neurodegenerative disorders such 
as Alzheimer's disease. Future knowledge of the impact of COVID-19, from epidemiological 
studies and clinical practice, will be needed to develop future screening and treatment 
programmes to minimize the long-term cognitive consequences of COVID-19. 
Key words: COVID-19, neuropathology, cognition, hippocampus, coronavirus
Abbreviations: 
AD Alzheimer’s disease
ARDS Acute respiratory distress syndrome
COVID-19 Coronavirus disease 19
HcoV Human coronaviruses
MERS-CoV Middle East respiratory syndrome
PTSD Post-traumatic stress syndrome
SARS-CoV Severe acute respiratory syndrome
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3The majority of persons suffering from COVID-19 will recover; recovery being principally 
defined in terms of remission of respiratory tract symptoms. But is this the end of the story for 
these patients ? There is increasing evidence that coronaviruses spread to extra-respiratory 
organs, notably the central nervous system (CNS) (Bohmwald et al., 2018; Desforges et al., 
2014, 2020), however, little is currently known about the longer-term effects on the brain of 
coronavirus infection and its consequences in terms of cognitive functioning. The scarcity of 
research in this area precludes formal meta-analysis, yet a number of observations from a 
systematic literature search suggest this to be potentially an important question for both 
clinical research and post-infection patient management.  A literature search was undertaken 
from 2000 to ensure coverage of the principal recent coronavirus epidemics using Medline, 
SCOPUS and Google Scholar data bases.
Neurological symptoms and sub-clinical cognitive dysfunction in the aftermath of COVID-19 
infection are likely to result from multiple and interacting causes, notably direct damage by 
the virus to the cortex and adjacent subcortical structures, indirect effects due to non-CNS 
systemic impairment and psychological trauma. 
Virus-induced CNS damage
Human coronaviruses (HcoV) are one of several virus groups which are considered to be 
potentially neurotrophic. It has been observed from previous epidemics that the respiratory 
coronaviruses may penetrate into the brain and cerebrospinal fluid, permeating the central 
nervous system in less than a week, and subsequently observable in cerebrospinal fluid 
(Bohmwald et al., 2018). An autopsy series of severe acute respiratory syndrome (SARS-
CoV) victims following the 2003 epidemic revealed SARS-CoV genome sequences 
throughout the cortex and hypothalamus (Gu et al., 2005). In patients infected by Middle East 
respiratory syndrome (MERS-CoV), diffuse lesions were identified in several brain regions, 
https://mc.manuscriptcentral.com/braincom
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/advance-article-abstract/doi/10.1093/braincom
m
s/fcaa069/5848404 by guest on 29 M
ay 2020
4including white matter and the subcortical areas of the frontal, temporal and parietal lobes 
(Arbi et al., 2015). Two principal mechanisms of CNS invasion have been proposed : 
(i) The blood-brain barrier, the first line of defense against viral infection, is 
composed in part of cerebral microvascular endothelium cells between which there 
are tight junctions controlling barrier permeability which appear to be 
compromised in the course of coronavirus infection, for example by inflammation 
(Koyuncu et al., 2013; Miner and Diamond 2016). 
(ii) The virus may directly infect neurons in the periphery or olfactory sensory 
neurones and thus use axonal transport to gain access to the CNS (Dahm et al., 
2016). 
Coronaviruses produce a wide variety of acute CNS symptoms including headaches, epileptic 
seizures, cognitive dysfunction, motor difficulties and loss of consciousness, and may also 
contribute to respiratory difficulties through invasion of the brain stem and via a synapse-
connected route to the medullary cardiorespiratory center (Bohmwald et al., 2018; Arbi et al., 
2015; Li et al., 2020; Gandhi et al., 2020). Although no clear aetiological  pathway has been 
established between infection and  human neurological diseases, the neuropathogenicity of 
HCoV is being increasingly recognized in humans, with several recent reports associating 
positive cases with multiple neurological disorders including encephalitis (Morfopoulou et al., 
2016), and Guillain–Barré syndrome (Sharma et al., 2019). Other strains of coronavirus (e.g. 
229E) have also been found in the brains of patients with Multiple Sclerosis (Arbour et al., 
2000). The presence and persistence of HCoV in human brains also appears to aggravate 
chronic neurological disorders such as Parkinson’s disease (Fazzini et al., 1992). Already 
several clinical observations have been published regarding the neurological consequences of 
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5the current COVID-19 epidemic, including reports of loss of speech and comprehension, 
encephalopathy (Filatov et al., 2020) and  Guillain-Barre syndrome (Zhao et al., 2020). 
While HCoV infection appears to spread rapidly throughout the CNS, the temporal region 
appears to be a consistent focus. Animal studies point more specifically to the vulnerability of 
the hippocampus with greater neuronal loss in CA1 and CA3 (Jacomy et al., 2006) which 
would be predicted to have a detrimental effect on both learning and spatial orientation. The 
specific vulnerability of the hippocampus to respiratory virus infection has been previously 
observed in non-coronavirus infections. Studies of mice infected with influenza virus 
(Hosseini et al., 2018) found changes in both hippocampal morphology and function, with 
short-term deterioration in hippocampus-dependent learning and reduced long-term 
potentiation associated with impairment in spatial memory. To date comprehensive 
neuropsychological assessment of patients, which would include tests of whole hippocampal 
function (such as tests of delayed recall or spatial memory) as well as novel tests probing 
hippocampal sub-regions such as tests of spatial memory which may aid detection of CA1 
damage (Bartsch et al., 2010) and a pattern completion task assessing CA3 function (Gold 
and Kesner 2005; Grande et al., 2019), has not been carried out in relation to HCoV.
If hippocampal damage is indeed a consequence of HCoV infection then the question is raised 
as to whether this may lead to acceleration of hippocampal-related degeneration as occurs in 
Alzheimer’s disease (AD) and hasten disease onset in previously asymptomatic individuals.  
Animal studies have indicated that inflammation related to viral infection significantly 
worsens AD-related tau pathology and results in impairment of spatial memory (Sy et al., 
2011), now considered to be one of the first cognitive features of Alzheimer’s disease.
Cognitive dysfunction due to non-CNS systemic impairment
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6Although numerous body organs are affected by coronaviruses, the respiratory system is the 
most severely compromised. A small study has recently estimated that 70% of critically ill 
patients admitted to intensive care with COVID-19 require mechanical ventilation (Arentz et 
al., 2020), all of whom developed acute respiratory distress syndrome (ARDS) within three 
days. Previous neuropsychological studies of long-term outcomes for adults requiring 
ventilation for multiple causes observed impairments in attention, memory, verbal fluency, 
processing speed and executive functioning in 78% of patients one year after discharge and 
around half of patients up to two years (Mikkelsen et al., 2012; Hopkins et al., 1999, 2005). 
Adhikari et al. (2011) observed self-reported memory problems persisting up to five years 
after ARDS and impacting significantly on everyday functioning, notably taking medication 
and keeping medical appointments. While anxiety, depression and post-traumatic stress 
syndrome (PTSD) are also common in ARDS patients, and may contribute to cognitive 
impairment (Adhikari et al., 2011), there is some evidence to suggest that cognitive deficits 
occur independently of psychological problems, and are associated with severity of infection 
(Mikkelsen et al., 2012). 
Hypoxia, a common cause of neuropsychological changes observed in ARDS, has been 
associated with cerebral atrophy and ventricular enlargement (Hopkins et al. 2006), with 
duration of hypoxia correlating with attention, verbal memory and executive functioning 
scores at discharge (Hopkins et al., 2005). However, ARDS may also involve inflammatory 
responses (Han and Mallampalli 2015) as well as anemia and ischemia, leading to 
cardiovascular and liver failure (Matthay and Zemans 2011). Such a cascade of neurological 
and physiological events may further exacerbate neurological injury in acute stages to 
promote chronic cognitive dysfunction.   
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7Cognitive difficulties related to psychological distress
Cognitive difficulties are symptomatic features of all mental disorders. High rates of 
psychological symptoms, notably anxiety, depression, suicidal behaviour and PTSD have 
been reported in the general population following previous HCoV epidemics, irrespective of 
infectious status (Jeong et al., 2016; Du et al. 2003). A study of patients quarantined for 
suspected or confirmed MERS-CoV (n=40), estimated that 70.8% of confirmed patients who 
survived the illness (n=24) exhibited psychiatric symptoms, including hallucinations and 
psychosis, with 40% receiving a psychiatric diagnosis during their hospital admittance. 
Interestingly, none of the suspected but unconfirmed MERS-CoV patients exhibited any 
symptoms (Kim et al., 2018), indicating a possible viral mechanism underlying psychiatric 
disturbance, a dose response effect or a greater psychological impact from receiving a 
confirmed respiratory illness diagnosis.  A study of 90 SARS-CoV cases with a 97% response 
rate similarly  showed high levels of psychological distress with 59% diagnosed with 
psychiatric disorders and a continuing prevalence of 33% at 30 month follow-up. Severity of 
psychological symptoms was found to be related to severity of illness and functional 
impairment (Mak et al., 2009; Wing and Leung 2012). 
Thus while higher rates of psychiatric symptoms might be expected in the general population 
following the epidemic due to exposure to traumatic life events (loss of income, fear, death of 
friends and relatives), nested within this group may be persons whose cognitive and 
psychological disorders are directly related to HCoV brain changes. The question might then 
be raised as to whether the latter group will respond to standard treatment for example with 
anti-depressants, anxiolytics and cognitive therapies. 
The small amount of information available from animal studies and previous respiratory 
epidemics suggests not only that HCoV may affect the brain, but that the consequent effect on 
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8cognitive functioning could potentially persist for a long period following recovery. For 
infected persons already suffering from CNS disorders the effects are likely to be even more 
debilitating. While new cases of well-characterized neurological disorders subsequent to the 
current epidemic may be relatively easy to identify, persisting sub-clinical disorders such as 
mild cognitive dysfunction, selective memory and speech impairments or exacerbation of pre-
existing degenerative neuropathologies such as vascular dementia and Alzheimer’s disease, 
presenting principally in general practice, may easily go undetected or be attributed to 
psychological reactions to the fear and social upheaval generated by the pandemic.
Conclusion
In the face of increasing reports of central nervous system involvement in COVID-19 cases, 
the current epidemic is likely to be accompanied by a significant increase in the prevalence of 
longer-term cognitive dysfunction impacting on ability to return to everyday functioning. This 
is likely to be due not only to the behavioural consequences of incident neurological disorders 
directly related to the virus, but also secondary to damage to other body organs, psychiatric 
disorders and the worsening of pre-existing cognitive difficulties. The number of persons 
exposed to the virus likely to be affected and the protective factors operating in cases who do 
not experience cognitive changes is presently unknown. Studies of cognitive dysfunction 
related to previous epidemics are few and too small to make estimations at a population level.
Further research is needed to understand (i) the range of  COVID-19 associated neurological 
disorders and their cognitive manifestations;  (ii) the underlying associations between viral 
spread, associated proinflammatory changes and disease pathogenesis; (iii) the duration and 
extent of neurological and cognitive changes following resolution of the acute viral illness; 
(iv) the association between severity of the viral illness and subsequent  cognitive 
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9dysfunction; (v) the effect of antiviral, psychological and other interventions (when available) 
on short and long term cognitive function. 
The current coronavirus outbreak is unlikely to be the last (with SARS and MERS, COVID-
19 this is the third coronavirus epidemic in 10 years). It is therefore imperative that the 
medical-scientific community look beyond the current acute crisis to the links between 
coronavirus infection and long term neurological sequelae. While basic science research will 
deliver insights into potential mechanistic relationships between viral infections and 
neurological disease, better understanding of these associations may inform treatment plans 
aimed both at treating the acute infection and limiting downstream cognitive decline. For 
instance, if future work showed  that viral load and/or subsequent proinflammatory state 
correlated with long term cognitive outcome then in future outbreaks treatment protocols 
could mitigate against the latter by adjusting the dose and duration of antiviral therapies or 
add second stage anti-inflammatory treatments.
This research could be taken forward in several ways. Existing longitudinal studies of 
neurological disorders could be expanded to include acquisition of data concerning COVID-
19 exposure and antibody status into existing research protocols which already capture data on 
cognitive function, brain imaging and disease biomarkers. Data from large prospective 
cohorts such as UK Biobank could provide population-scale data with clearer information 
regarding prevalence and persistence of effects over extensive timelines. In parallel, 
preclinical studies aimed at uncovering the mechanistic association between coronavirus 
infection and neurological disease will be facilitated by the recent creation of mouse models 
of COVID-19, which will enable assessment of the interaction between viral pathology and 
neurodegeneration and will provide a resource for the development of new treatments (Wang 
et al., 2020). These will be complemented by the accumulation of information about disease 
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onset and clinical progression, particularly from general practice, which will be crucially 
important for the implementation of future population-level screening and treatment 
programmes. 
The scope and severity of the current COVID-19 pandemic is unparalleled in modern society. 
The downstream implications for neurological function may be equally grave. While the 
current focus is on acute disease management, in the near future attention will need to turn to 
the long term consequences of COVID-19 infection and their mitigation.  
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Abbreviated summary
Clinical reports have shown that human coronaviruses may cause acute and chronic cognitive 
dysfunction due to direct infection of the brain, indirectly through respiratory system 
pathology and as a result of psychological disorders. Further understanding of the cognitive 
consequences of COVID-19 and associated brain changes may inform future treatment 
strategies.
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